Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer

Elsayed M Ali; Emad Eldin Nabil; Ashraf Elyamany; Ahmed M. Maklad; Ahmed Gaber Abdelraheem

doi:doi:10.11648/j.jctr.20140204.12

| Peer-Reviewed

Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer

Elsayed M Ali, Emad Eldin Nabil, Ashraf Elyamany, Ahmed M. Maklad, Ahmed Gaber Abdelraheem

Published in Journal of Cancer Treatment and Research (Volume 2, Issue 4)

Received: 4 August 2014 Accepted: 20 August 2014 Published: 30 August 2014

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

PURPOSE: In our study we compared low-dose gemcitabine-based chemoradiotherapy with cisplatin-based chemoradiotherapy as regards response rate, survival and toxicity profile in locally advanced head and neck cancer. Methodology: sixty patients with locally advanced head and neck cancer were included in this prospective comparative randomized study, in the period from January 2011 to September 2013. Results: The patients were treated in two randomized groups; each of them included 30 patients. In gemcitabine arm (group A), 42.3% of the patients had stage III, and 57.7% of them had stage IVa while 48.15% of the patients of cisplatin arm (group B) had stage III and 51.85% had stage IVa. The median duration of response in group A was 21 months, while in group B it was 23 months. The degree of response had a statistically significant effect on survival in group B patients. It was evident in patients who achieved partial response (PR) that showed lower survival than those with (CR). Conclusion: Gemcitabine has comparable radiosensitizing effect with acceptable toxicity profile and can be used as a radiosensitizer in head and neck cancers especially when cisplatin cannot be used. We recommend further studies to establish its rule.

Published in	Journal of Cancer Treatment and Research (Volume 2, Issue 4)
DOI	10.11648/j.jctr.20140204.12
Page(s)	37-44
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Head and Neck, Radiotherapy, Chemotherapy, Gemcitabine, Cisplatin

References

[1]	Parkin DM1, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005;55:74-108.
[2]	Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer the United States: a site-specific analysis of the SEER database. Int J Cancer 2005;114:806-816.
[3]	Bourhis J, Le Maitre A, Baujat B, et al. Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol 2007; 19:188.
[4]	Bruce Brockstein Everett E. Vokes. Concurrent chemoradiotherapy for head and neck cancer. Seminars in Oncology ,Volume 31, Issue 6 , Pages 786-793, December 2004.
[5]	Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945-1952.
[6]	Eisbruch A, Shewach DS, Urba S, et al. Phase I trial of radiation concurrent with low-dose gemcitabine for head and neck cancer: high mucosal and pharyngeal toxicity. Proc Am Soc Clin Oncol 1997; 16: 386a (Abstr 1377).
[7]	Aguilar-Ponce JL, Granados-Garcia M, Villavicencio V, et al. phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2004; 15:301-306.
[8]	Ali E M and Abdelraheem AG Concurrent radiotherapy and chemotherapy for locally advanced squamous cell carcinoma of the head and neck Head & Neck Oncology 2011, 3:48
[9]	Shaharyar, Abrar Ahmed Javed, Ijaz Hussain Shah, et al. Department of Clinical Oncology, King Edward Medical College / Mayo Hospital, Lahore. Pak J Med Sci July - September 2006 Vol. 22 No. 3 258-264.
[10]	Sirisinha D, Rybicki LA, Wood BJ, et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 2006; 24: 1064–1071.
[11]	Mohamed Abd El-Aziz Sonosy, Mohamed Saad Zaghloul Rafat Ali Saber, et al. Phase II trial of Radiotherapy Concurrent with Low Dose Gemcitabine for Management of Locally Advanced Non-resectable Head and Neck Cancer; Faculty of Medicine Minia University; 2007.
[12]	Ashok Chauhan, Harmeet Singh, Tejpal Sharma, et al. Afr Health Sci. September; 2008; 8(3): 149–155.
[13]	Eisbruch A, Shewach DS, Urba S, et al. Phase I trial of radiation concurrent with low-dose gemcitabine for head and neck cancer: high mucosal and pharyngeal toxicity. Proc Am Soc Clin Oncol 1997; 16: 386a (Abstr 1377).
[14]	R Sharma, D Abrol, S Kaur, et al. J Clin Oncol 26: 2008 (May 20 suppl; abstr 17032).
[15]	Adelstein DJ, Li Y, Adams GL, et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21:92-98.
[16]	Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349:2091-2098.
[17]	Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol; 1998; 16:1310-1317.
[18]	Sanchiz F, et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990; 19: 1347–1350.
[19]	Lovey J, et al. Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. Radiotherapy Oncology 2003; 68: 171–174.
[20]	Pergolizzi S, et al. Induction chemotherapy to weekly paclitaxel concurrent with curative radiotherapy in stage IV (M0) unresectable head and neck squamous cell carcinoma: a dose escalation study. J Chemother 2004; 16: 201–205.
[21]	Calais G, et al. Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial. Int J Radiat Oncol Biol Phys 2004; 58: 161–166.
[22]	Adelstein DJ, Saxton JP, Rybicki LA, et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 2006; 24: 1064–1071.
[23]	Garden AS et al. (2004) Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004; 22: 2856–2864.
[24]	Carter DL, et al. Two year survival for concurrent carboplatin, paclitaxel, and hyperfractionated radiotherapy in unresectable head and neck cancer [abstract # 2028]. Proc Am Soc Clin Oncol 2003; 22: 2028.
[25]	Denis F et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69–76.
[26]	Staar S et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy—results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1161–1171

Cite This Article

Plain Text BibTeX RIS

APA Style

Elsayed M Ali, Emad Eldin Nabil, Ashraf Elyamany, Ahmed M. Maklad, Ahmed Gaber Abdelraheem. (2014). Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer. Journal of Cancer Treatment and Research, 2(4), 37-44. https://doi.org/10.11648/j.jctr.20140204.12

Copy | Download

ACS Style

Elsayed M Ali; Emad Eldin Nabil; Ashraf Elyamany; Ahmed M. Maklad; Ahmed Gaber Abdelraheem. Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer. J. Cancer Treat. Res. 2014, 2(4), 37-44. doi: 10.11648/j.jctr.20140204.12

Copy | Download

AMA Style

Elsayed M Ali, Emad Eldin Nabil, Ashraf Elyamany, Ahmed M. Maklad, Ahmed Gaber Abdelraheem. Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer. J Cancer Treat Res. 2014;2(4):37-44. doi: 10.11648/j.jctr.20140204.12

Copy | Download

@article{10.11648/j.jctr.20140204.12,
  author = {Elsayed M Ali and Emad Eldin Nabil and Ashraf Elyamany and Ahmed M. Maklad and Ahmed Gaber Abdelraheem},
  title = {Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer},
  journal = {Journal of Cancer Treatment and Research},
  volume = {2},
  number = {4},
  pages = {37-44},
  doi = {10.11648/j.jctr.20140204.12},
  url = {https://doi.org/10.11648/j.jctr.20140204.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20140204.12},
  abstract = {PURPOSE: In our study we compared low-dose gemcitabine-based chemoradiotherapy with cisplatin-based chemoradiotherapy as regards response rate, survival and toxicity profile in locally advanced head and neck cancer. Methodology: sixty patients with locally advanced head and neck cancer were included in this prospective comparative randomized study, in the period from January 2011 to September 2013. Results: The patients were treated in two randomized groups; each of them included 30 patients. In gemcitabine arm (group A), 42.3% of the patients had stage III, and 57.7% of them had stage IVa while 48.15% of the patients of cisplatin arm (group B) had stage III and 51.85% had stage IVa. The median duration of response in group A was 21 months, while in group B it was 23 months. The degree of response had a statistically significant effect on survival in group B patients. It was evident in patients who achieved partial response (PR) that showed lower survival than those with (CR). Conclusion: Gemcitabine has comparable radiosensitizing  effect with acceptable toxicity profile and can be used as a radiosensitizer in head and neck cancers especially when cisplatin cannot be used. We recommend further studies to establish its rule.},
 year = {2014}
}

Copy | Download

TY - JOUR
T1 - Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer
AU - Elsayed M Ali
AU - Emad Eldin Nabil
AU - Ashraf Elyamany
AU - Ahmed M. Maklad
AU - Ahmed Gaber Abdelraheem
Y1 - 2014/08/30
PY - 2014
N1 - https://doi.org/10.11648/j.jctr.20140204.12
DO - 10.11648/j.jctr.20140204.12
T2 - Journal of Cancer Treatment and Research
JF - Journal of Cancer Treatment and Research
JO - Journal of Cancer Treatment and Research
SP - 37
EP - 44
PB - Science Publishing Group
SN - 2376-7790
UR - https://doi.org/10.11648/j.jctr.20140204.12
AB - PURPOSE: In our study we compared low-dose gemcitabine-based chemoradiotherapy with cisplatin-based chemoradiotherapy as regards response rate, survival and toxicity profile in locally advanced head and neck cancer. Methodology: sixty patients with locally advanced head and neck cancer were included in this prospective comparative randomized study, in the period from January 2011 to September 2013. Results: The patients were treated in two randomized groups; each of them included 30 patients. In gemcitabine arm (group A), 42.3% of the patients had stage III, and 57.7% of them had stage IVa while 48.15% of the patients of cisplatin arm (group B) had stage III and 51.85% had stage IVa. The median duration of response in group A was 21 months, while in group B it was 23 months. The degree of response had a statistically significant effect on survival in group B patients. It was evident in patients who achieved partial response (PR) that showed lower survival than those with (CR). Conclusion: Gemcitabine has comparable radiosensitizing effect with acceptable toxicity profile and can be used as a radiosensitizer in head and neck cancers especially when cisplatin cannot be used. We recommend further studies to establish its rule.
VL - 2
IS - 4
ER -

Copy | Download

Author Information

Elsayed M Ali

Clinical Oncology Department, Sohag University, Sohag, Egypt
Emad Eldin Nabil

Clinical Oncology Department, Sohag University, Sohag, Egypt
Ashraf Elyamany

Medical Oncology Department SECI, Assiut University, Assiut, Egypt, KFMC, KSA
Ahmed M. Maklad

Clinical Oncology Department, Sohag University, Sohag, Egypt, KFMC, KSA
Ahmed Gaber Abdelraheem

ENT Department, Faculty of Medicine, South Valley University, Qena, po 83523, Egypt

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Elsayed M Ali, Emad Eldin Nabil, Ashraf Elyamany, Ahmed M. Maklad, Ahmed Gaber Abdelraheem. (2014). Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer. Journal of Cancer Treatment and Research, 2(4), 37-44. https://doi.org/10.11648/j.jctr.20140204.12

Copy | Download

ACS Style

Elsayed M Ali; Emad Eldin Nabil; Ashraf Elyamany; Ahmed M. Maklad; Ahmed Gaber Abdelraheem. Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer. J. Cancer Treat. Res. 2014, 2(4), 37-44. doi: 10.11648/j.jctr.20140204.12

Copy | Download

AMA Style

Elsayed M Ali, Emad Eldin Nabil, Ashraf Elyamany, Ahmed M. Maklad, Ahmed Gaber Abdelraheem. Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer. J Cancer Treat Res. 2014;2(4):37-44. doi: 10.11648/j.jctr.20140204.12

Copy | Download

@article{10.11648/j.jctr.20140204.12,
  author = {Elsayed M Ali and Emad Eldin Nabil and Ashraf Elyamany and Ahmed M. Maklad and Ahmed Gaber Abdelraheem},
  title = {Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer},
  journal = {Journal of Cancer Treatment and Research},
  volume = {2},
  number = {4},
  pages = {37-44},
  doi = {10.11648/j.jctr.20140204.12},
  url = {https://doi.org/10.11648/j.jctr.20140204.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20140204.12},
  abstract = {PURPOSE: In our study we compared low-dose gemcitabine-based chemoradiotherapy with cisplatin-based chemoradiotherapy as regards response rate, survival and toxicity profile in locally advanced head and neck cancer. Methodology: sixty patients with locally advanced head and neck cancer were included in this prospective comparative randomized study, in the period from January 2011 to September 2013. Results: The patients were treated in two randomized groups; each of them included 30 patients. In gemcitabine arm (group A), 42.3% of the patients had stage III, and 57.7% of them had stage IVa while 48.15% of the patients of cisplatin arm (group B) had stage III and 51.85% had stage IVa. The median duration of response in group A was 21 months, while in group B it was 23 months. The degree of response had a statistically significant effect on survival in group B patients. It was evident in patients who achieved partial response (PR) that showed lower survival than those with (CR). Conclusion: Gemcitabine has comparable radiosensitizing  effect with acceptable toxicity profile and can be used as a radiosensitizer in head and neck cancers especially when cisplatin cannot be used. We recommend further studies to establish its rule.},
 year = {2014}
}

Copy | Download